REFERRAL

BCR::ABL1 Kinase Domain Mutation Analysis

SA PATHOLOGY

Reset Form | Save As

barcode | Lab No. Sticker

PATIENT DETAILS

Patient Name: Date of Birth:

COLLECTION DETAILS

Collection Date:

Sample type ☐ Peripheral blood ☐ Bone marrow ☐ Other (list)

Sample sent as ☐ Ambient (EDTA) ☐ Trizol (frozen) ☐ RNA ☐ Other *(list)*

BCR::ABL1 INFORMATION

BCR::ABL1 transcript type

☐ e13a2 ☐ e14a2 ☐ e13a2/e14a2 ☐ e1a2

☐ Atypical transcript *(define, e.g. e19a2, e6a2)*

Patient status

☐ CML-CP ☐ CML-AP ☐ CML-BC ☐ Ph+ALL ☐ Other *(list)*

Current treatment ☐ Imatinib ☐ Dasatinib ☐ Nilotinib ☐ Ponatinib ☐ Asciminib ☐ Bosutinib

☐ None ☐ Other (list)

Most recent BCR::ABL1 result:

Collection Date: BCR::ABL1 % international scale:

Previous history of BCR::ABL1 mutations? ☐ No ☐ Yes *(list mutations)*

REFERRAL INFORMATION

☐ Clinical notes for BCR::ABL1 mutation analysis are clearly indicated on the pathology request form OR

☐ Please provide supporting information for your mutation analysis request
(For example-rising BCR::ABL1 levels, poor response to treatment etc.)

REQUESTOR'S DETAILS

Name: Phone:

Email:

INCOMPLETE INFORMATION

Missing or incomplete information on this referral could result in substantial delay in processing, or cancellation of the request.

SAMPLE SUBMISSION

When complete please send this referral form together with a pathology request form and the sample to:

Genetics and Molecular Pathology, SA Pathology, Frome Road, Adelaide SA 5000

OR email *(preferred)* to Health.SAPathologyLeukaemiaUnit@sa.gov.au OR fax (08) 8222 3146.

ADDITIONAL INFORMATION

If you require more information please phone the laboratory on (08) 8222 3892.

Refer overleaf for test information and billing.

Sample requirements and test billing

This test requires adequate quality of RNA, and sufficient BCR::ABL1 % to be performed.

- Blood or bone marrow should be received ambient by our lab within 48 hours of collection, or stabilised locally (trizol) in the same time frame before being sent frozen.
- BCR::ABL1 limit of testing is >0.1%IS (Major Molecular Response). Lower levels may be attempted if clinical indication warrants testing despite the low level, however these are highly likely to fail testing.
- This test is performed to detect emergence of BCR::ABL1 kinase domain mutations associated with resistance to treatment, and is not warranted on pre-treatment / diagnosis samples. Requests will be cancelled if clinical notes indicate the sample was collected at diagnosis or prior to commencing first-line therapy.

If this referral indicates the BCR::ABL1 level is insufficient to perform the analysis, the test will be cancelled, and no charge will apply. The requestor will be contacted (providing the contact information is supplied on the referral), and the sample will be stored for 2 months and then discarded.

Please Note: An interim analysis is performed on all samples to determine RNA quality and BCR::ABL1 % of the specific sample received.

- If the RNA is degraded to a level that we are unable to perform the analysis accurately, the test will be cancelled, and a report issued. **A charge will still apply**.
- If the level of BCR::ABL1 is found to be inadequate to perform the testing, the test will be cancelled, and a report issued. **A charge will still apply**.

In some cases (approximately 5% of requests), the RNA quality and BCR::ABL1 level are suitable, but the testing repeatedly fails. This may be due to an unknown biological cause specific to the sample collected, or unknown inhibitors that interfere with the test procedure. If testing has been performed, but we are repeatedly unable to obtain a result, a report will be issued. **A charge will still apply**.

By submitting this request you acknowledge and accept these charges.